Business Wire

FLEXTRADE-SYSTEMS

24.5.2023 09:31:31 CEST | Business Wire | Press release

Share
FlexTrade Breaks New Ground with Artificial Intelligence Functionality Available in FlexTRADER EMS

FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, has announced the launch of artificial intelligence-driven (AI) functionality within its flagship multi-asset solution, FlexTRADER EMS. The new interface layer is designed to revolutionize how trading teams interact with their data and trading technology solutions.

Over the past year, OpenAI driven-solutions such as ChatGPT and its latest version, GPT-4, which apply natural language processing to large language model (LLM) systems, have been in the spotlight, with firms racing to understand their uses for the trading space. However, the new offering from FlexTrade is one of the first practical examples of the technology being used directly within an OEMS solution.

The groundbreaking innovation, which has the working name of FlexA, is a voice-activated application developed by FlexTrade's in-house data science team as part of its ongoing R&D function and commitment to delivering innovation to its customer base. The solution provides an AI layer across FlexTRADER EMS to simplify the interaction between the trader and their trading technology platform and easily and intuitively work with vast swathes of information outside the more traditional 2D grid visualization and input devices currently used.

With the new solution, traders using FlexTRADER EMS, with FlexA enabled, can apply natural language to interrogate and control the solution via voice commands or a text-based chat interface in several ways. For instance, clients can ask verbal or written questions to quickly and easily achieve a deep situational awareness of orders within their blotter using a combination of specific criteria or characteristics such as "What is the value of my Swiss orders over 10% ADV?". Additionally, traders can request ad-hoc reports on historical trading with specific visualization formats, including tables and charts, to assist with pre-trade decision-making. For example: "Show me a chart of my traded venues for US orders in Feb." Furthermore, traders can send actions to be automated to help speed up workflow. For instance, "create a ticket for my US orders less than 500k using the VWAP AlgoWheel" or "merge AAPL."

Vijay Kedia, CEO, FlexTrade Systems Inc., stated: "The introduction of OpenAI and ChatGPT is a revolutionary moment in consumer technology, and the speed at which we've incorporated it across FlexTRADER EMS is a milestone achievement. It enables traders to use natural language to rapidly interact, interrogate and understand data in the manner which makes the most sense to them. The outcome is that it erodes the barriers created by traditional input devices such as keyboard and mouse, enabling trading teams to work quickly to understand and optimize their pre-trade decisions, which is paramount in a constantly changing environment."

Vikas Kedia, Managing Director of Strategic Initiatives & Emerging Solutions at FlexTrade, commented: "FlexTrade's R&D and innovation teams continuously and proactively evaluate the latest technologies, as they become available, to understand the practical applications to buy-and-sell-side trading desks. From machine learning and our sophisticated real-time market impact analytics offering to, most recently, AI, we are working with our client base and business users to refine and explore further applications across global trading desks. It's an approach that ensures our clients stay at the forefront of cutting-edge developments in trading technology."

About FlexTrade Systems:

FlexTrade Systems is a global leader in high-performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world's first broker-neutral execution management trading system. It allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005117/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye